Ross Muken
Stock Analyst at Evercore ISI Group
(1.14)
# 2,677
Out of 4,829 analysts
40
Total ratings
40%
Success rate
-7.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ross Muken
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintains: In-Line | $190 → $225 | $143.08 | +57.25% | 6 | Nov 7, 2024 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $360 → $350 | $140.22 | +149.61% | 7 | Oct 8, 2024 | |
| HSIC Henry Schein | Maintains: In-Line | $70 → $74 | $70.47 | +5.01% | 8 | Oct 8, 2024 | |
| A Agilent Technologies | Maintains: In-Line | $126 → $130 | $115.55 | +12.51% | 11 | Jul 2, 2024 | |
| QGEN Qiagen | Downgrades: In-Line | n/a | $42.96 | - | 2 | Jul 16, 2019 | |
| CAH Cardinal Health | Initiates: In-Line | $67 | $148.62 | -54.92% | 2 | Jan 5, 2018 | |
| ILMN Illumina | Initiates: Outperform | $250 | $81.57 | +206.49% | 2 | Jan 4, 2018 | |
| TMO Thermo Fisher Scientific | Initiates: Outperform | $220 | $432.59 | -49.14% | 1 | Jan 4, 2018 | |
| MBLY Mobileye Global | Downgrades: In-Line | n/a | $16.61 | - | 1 | Mar 13, 2017 |
Charles River Laboratories International
Nov 7, 2024
Maintains: In-Line
Price Target: $190 → $225
Current: $143.08
Upside: +57.25%
ICON Public Limited Company
Oct 8, 2024
Maintains: Outperform
Price Target: $360 → $350
Current: $140.22
Upside: +149.61%
Henry Schein
Oct 8, 2024
Maintains: In-Line
Price Target: $70 → $74
Current: $70.47
Upside: +5.01%
Agilent Technologies
Jul 2, 2024
Maintains: In-Line
Price Target: $126 → $130
Current: $115.55
Upside: +12.51%
Qiagen
Jul 16, 2019
Downgrades: In-Line
Price Target: n/a
Current: $42.96
Upside: -
Cardinal Health
Jan 5, 2018
Initiates: In-Line
Price Target: $67
Current: $148.62
Upside: -54.92%
Illumina
Jan 4, 2018
Initiates: Outperform
Price Target: $250
Current: $81.57
Upside: +206.49%
Thermo Fisher Scientific
Jan 4, 2018
Initiates: Outperform
Price Target: $220
Current: $432.59
Upside: -49.14%
Mobileye Global
Mar 13, 2017
Downgrades: In-Line
Price Target: n/a
Current: $16.61
Upside: -